Drug development professionals rely on Tufts Center Impact Reports.

"Impact Reports provide timely, comprehensive summaries on 'hot' topics in a crisp, concise format. The use of bulleted summaries and visuals is exemplary."
Peter S. Ringrose
President
Bristol-Myers Squibb Company

"Impact Reports provide essential new information about key issues affecting drug development and regulatory affairs."
John C. Alexander, M.D., M.P.H.
Executive Vice President
Sankyo Pharma Inc.

"Every Impact Report provides comprehensible and insightful information on the current competitive and regulatory environment in the U.S. It's a publication I would not want to miss."
Kathrin A. Bergin, Ph.D.
Head, Regulatory Affairs
Aventis Pharmaceuticals

"You cannot have enough really good information and the Impact Reports provide that."
Michael A. Friedman, M.D.
Senior Vice President, Clinical Affairs
Pharmacia Corporation

"The Impact Reports are of excellent quality and a real asset as they provide insights and valuable analyses on topical areas of real importance to the pharmaceutical industry and regulators."
Steve Arlington, Ph.D.
Global Head, R&D Consulting
PricewaterhouseCoopers

"Impact Reports provide valuable position statements which have clarity and authority that I have not seen elsewhere."
Roger Bolton
Director, Scientific and Technical Policy
AstraZeneca

"Every Impact Report provides excellent and thoroughly investigated executive study summaries which I find very valuable for the global supervision of the strategic changes in our rapidly changing R&D environment."
Thomas R. Weihrauch, M.D., Ph.D., FFPM
Vice President of Global Medical Strategy and Relations
Bayer AG

"Impact Reports provide a rich, thoughtful, and timely assessment of crucial, specific, and comparative insights and data"
Frederick W. Telling, Ph.D.
VP, Planning and Policy for Pharmaceuticals
Pfizer Inc.